MX2010008364A - Composiciones y metodos para cristalizar fragmentos de anticuerpo. - Google Patents

Composiciones y metodos para cristalizar fragmentos de anticuerpo.

Info

Publication number
MX2010008364A
MX2010008364A MX2010008364A MX2010008364A MX2010008364A MX 2010008364 A MX2010008364 A MX 2010008364A MX 2010008364 A MX2010008364 A MX 2010008364A MX 2010008364 A MX2010008364 A MX 2010008364A MX 2010008364 A MX2010008364 A MX 2010008364A
Authority
MX
Mexico
Prior art keywords
crystallizing
methods
compositions
fab fragment
antibody fragments
Prior art date
Application number
MX2010008364A
Other languages
English (en)
Inventor
Chengbin Wu
Maria A Argiriadi
David W Borhani
Tariq Ghayur
Tao Xiang
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2010008364A publication Critical patent/MX2010008364A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
    • C30B29/54—Organic compounds
    • C30B29/58—Macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C07K1/306—Extraction; Separation; Purification by precipitation by crystallization
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente invención proporciona métodos para cristalizar anticuerpos y fragmentos de los mismos, así como cristales producidos de esta manera. Más particularmente la presente invención proporciona métodos para cristalizar fragmentos de anticuerpos Fab humanos y no humanos, ya sea solos o como co-cristales con su ligando objetivo. Por ejemplo, se proporciona un cristal que comprende un fragmento de múrido Fab del anticuerpo 125-2H o un fragmento Fab de humano del anticuerpo ABT-325, que enlaza a IL-18, así como un co-cristal de un fragmento Fab de múrido enlazado a IL-18. ABT-325 y 125-2H difieren significativamente en el carácter del sitio de combinación y en la arquitectura, explicando de esta forma su capacidad para enlazar a IL-18 en forma simultánea en epítopes distintos.
MX2010008364A 2008-01-30 2009-01-29 Composiciones y metodos para cristalizar fragmentos de anticuerpo. MX2010008364A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6288708P 2008-01-30 2008-01-30
US13573908P 2008-07-22 2008-07-22
PCT/US2009/000568 WO2009099545A1 (en) 2008-01-30 2009-01-29 Compositions and methods for crystallizing antibody fragments

Publications (1)

Publication Number Publication Date
MX2010008364A true MX2010008364A (es) 2010-08-23

Family

ID=40939064

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010008364A MX2010008364A (es) 2008-01-30 2009-01-29 Composiciones y metodos para cristalizar fragmentos de anticuerpo.

Country Status (7)

Country Link
US (1) US20090202557A1 (es)
EP (1) EP2247310A4 (es)
JP (1) JP2011511777A (es)
CN (1) CN102065892A (es)
CA (1) CA2713342A1 (es)
MX (1) MX2010008364A (es)
WO (1) WO2009099545A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2270030C2 (ru) 1996-02-09 2006-02-20 Абботт Байотекнолоджи эЛтиди. СПОСОБ ИНГИБИРОВАНИЯ АКТИВНОСТИ ЧЕЛОВЕЧЕСКОГО TNFα (ВАРИАНТЫ), ПРИМЕНЕНИЕ ВЫДЕЛЕННОГО АНТИТЕЛА ЧЕЛОВЕКА ИЛИ ЕГО АНТИГЕНСВЯЗЫВАЮЩЕГО ФРАГМЕНТА В КАЧЕСТВЕ КОМПОНЕНТА ДЛЯ ПРОИЗВОДСТВА ЛЕКАРСТВЕННОГО СРЕДСТВА (ВАРИАНТЫ) И ВЫДЕЛЕННОЕ ЧЕЛОВЕЧЕСКОЕ АНТИТЕЛО ИЛИ ЕГО АНТИГЕНСВЯЗЫВАЮЩИЙ ФРАГМЕНТ
NZ591701A (en) 2005-05-16 2012-11-30 Abbott Biotech Ltd Use of tnf inhibitor for treatment of erosive polyarthritis
US9605064B2 (en) * 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
BRPI0717335A2 (pt) 2006-10-27 2013-12-10 Abbott Biotech Ltd Anticorpos anti-htnfalfa cristalinos
NZ598881A (en) * 2007-03-29 2013-11-29 Abbvie Inc Crystalline anti-human il-12 antibodies
US8753839B2 (en) 2007-08-08 2014-06-17 Abbvie Inc. Compositions and methods for crystallizing antibodies
BR112013003279A2 (pt) * 2010-08-13 2016-06-14 Genentech In “métodos para tratar uma doença, método para neutralizar ou bloquear a atividade de il-1ß e/ou il-18, anticorpo, usos de um anticorpo e usos de um anticorpo monoclonal”
WO2012022804A1 (en) * 2010-08-19 2012-02-23 Probiodrug Ag Crystal structure of glutaminyl cyclase
KR20140003467A (ko) * 2010-12-20 2014-01-09 메디뮨 리미티드 항il-18 항체 및 그의 용도
EP2702077A2 (en) 2011-04-27 2014-03-05 AbbVie Inc. Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
US20150175974A1 (en) * 2012-06-11 2015-06-25 Syngenta Participations Ag Producing solids and related mother liquors
KR20150043523A (ko) 2012-09-02 2015-04-22 애브비 인코포레이티드 단백질 불균일성의 제어 방법
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
EP2830651A4 (en) 2013-03-12 2015-09-02 Abbvie Inc HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
AR095863A1 (es) * 2013-04-16 2015-11-18 Genentech Inc Variantes de pertuzumab, su evaluación, método de tratamiento, método de preparación y artículo de fabricación
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
WO2015073884A2 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
GB201409451D0 (en) 2014-05-28 2014-07-09 Ipabc Ltd Antimicrobial preparations, methods for preparing the same and uses thereof to combat microorganisms

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030074693A (ko) * 2000-12-28 2003-09-19 알투스 바이올로직스 인코포레이티드 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
WO2004094020A2 (en) * 2003-04-17 2004-11-04 Fluidigm Corporation Crystal growth devices and systems, and methods for using same
US20050100965A1 (en) * 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
RU2515108C2 (ru) * 2005-08-19 2014-05-10 Эббви Инк Иммуноглобулин с двойными вариабельными доменами и его применения
BRPI0717335A2 (pt) * 2006-10-27 2013-12-10 Abbott Biotech Ltd Anticorpos anti-htnfalfa cristalinos
NZ598881A (en) * 2007-03-29 2013-11-29 Abbvie Inc Crystalline anti-human il-12 antibodies

Also Published As

Publication number Publication date
EP2247310A1 (en) 2010-11-10
JP2011511777A (ja) 2011-04-14
CA2713342A1 (en) 2009-08-13
WO2009099545A1 (en) 2009-08-13
CN102065892A (zh) 2011-05-18
US20090202557A1 (en) 2009-08-13
EP2247310A4 (en) 2012-06-27

Similar Documents

Publication Publication Date Title
MX2010008364A (es) Composiciones y metodos para cristalizar fragmentos de anticuerpo.
EA030777B9 (ru) Анти-альфа-синуклеинсвязывающие молекулы
MX2014001799A (es) Anticuerpos sin fc qie comprenden dos fragmentos fab y metodos de uso.
MX336197B (es) Anicuerpos anti-igf-1r y anti-erbb3 monoespecificos y biespecificos.
MX2009009450A (es) Anticuerpos monoclonales para he4 y metodos para su uso.
BRPI0607486A2 (pt) anticorpo l243 humanizado, anticorpo biespecìfico ou fragmentos de ligação a antìgeno dos mesmos, composição farmacêutica, kit e uso dos referidos anticorpos
MX2018008680A (es) Moleculas de union especifica a proteina de union a adn de respuesta transactiva de 43 kda (tdp-43).
PH12016500658B1 (en) Human anti-alpha-synuclein autoantibodies
BR112013011065A2 (pt) "anticorpo anti-il-23p19 ou seu fragmento de ligação ao antígeno, composição farmacêutica, uso de um anticorpo ou do fragmento de ligação, método para inibir a ligação da il-23 para o receptor da il-23 em uma célula de mamífero, polinucleotídeo isolado e kit"
DOP2010000334A (es) Anticuerpos contral el receptor de productos finales de glicosilacion avanzada (rage) y usos de los mismos
UA106070C2 (uk) Антитіло, що специфічно зв'язується з egfr і her3
MX353931B (es) Anticuerpos que se unen a ox40 y sus usos.
MX2012003598A (es) Anticuerpos biespecificos agonistas de receptores de muerte.
SG184310A1 (en) Antibodies that bind human cd27 and uses thereof
WO2014025546A3 (en) Anti-dengue virus antibodies and uses thereof
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
MX2010007935A (es) Anticuerpo monoclonal humanizado anti-nkg2a humano.
JP2014043446A5 (es)
AR062895A1 (es) Composiciones y metodos relacionados con los anticuerpos receptores de glucagon
BR112014005644A2 (pt) anticorpo anti-alfabetatcr
SG178886A1 (en) Humanized anti-cdcp1 antibodies
EA201070695A1 (ru) Молекулы гуманизированных антител, специфичных к il-31
WO2009128963A3 (en) Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
WO2010136311A3 (en) Compositions and methods for antibodies targeting complement protein c3b
EA201491120A1 (ru) Антитела к рецептору эпидермального фактора роста 3 (her3), направленные на домен iii и домен iv her3

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: ABBVIE INC.

FG Grant or registration